^
Association details:
| Biomarker: | EGFR negative + ALK negative |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tedopi (OSE 2101) (Immunostimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Prognostic factors of overall survival (OS) in non-small cell lung cancer (NSCLC) patients after failure on immune checkpoint inhibitors (IO) treated with anticancer vaccine OSE2101 or chemotherapy (CT) in phase 3 ATALANTE-1 randomized trial.
Published date:
05/25/2023
Excerpt:
118 NSCLC EGFR and ALK negative patients who progressed after sequential CT-IO and who received at least 12 weeks IO (defining IO secondary resistance), were randomized (2:1) in OSE2101 or SoC (docetaxel or pemetrexed)….best response to study treatment was CR/PR/SD, median OS with OSE2101 was 12.6 [8.8;16.8] months and 8.0 [5.5; 11.1] when best response was DP (HR 0.61 [0.36; 1.04]); with CT, median OS was respectively 9.8 [7.4; 13.8] and 5.0 [1.0; 7.2] months (HR 0.34 [0.14; 0.84].
Secondary therapy:
pemetrexed; docetaxel
DOI:
10.1200/JCO.2023.41.16_suppl.e21037
Trial ID:
